All of Us Research Program
Do you want to change the future of health? The Froedtert & MCW health network is part of the National Institutes of Health All of Us Research Program. It has a simple mission — speed up health research breakthroughs. To do this, All of Us is asking one million people to share their health information. Learn how you can help make a difference by joining the All of Us Research Program.
43 results for "Cancer" and "Gynecologic Cancers" and "Other Blood Related"
A Phase III, Randomized Study Of Nivolumab (OPDIVO) Plus AVD Or Brentuximab Vedotin (ADCETRIS) Plus AVD In Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
Nivo plus AVD or BV plus AVD in newly diagnosed advanced HL
Protocol No
SWOG-S1826-HL
Sub Category
Daratumumab, Pomalidomide And Dexamethasone (Dpd) In Relapsed/ Refractory Light Chain Amyloidosis Patients Previously Exposed To Daratumumab
DPd in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab
Protocol No
WEILLCORNELL-AMY2006-DPD
Sub Category
A Phase 3, Open-Label, Multicenter, Randomized, Active-controlled Study to Assess Pharmacokinetics and Compare the Efficacy, Safety, and Tolerability of P1101 vs Anagrelide as Second Line Therapy for Essential Thrombocythemia
Ropeginterferon Alfa-2b (P1101) v. Anagrelide in ET Patients w/Hydroxyurea Resistance or Intolerance
Protocol No
PHARMAESSENTIA-P1101-ET
Sub Category
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscrasia Treatment-Naïve Patients with Mayo Stage IIIb AL Amyloidosis
A Study to Evaluate the Effectiveness & Safety of CAEL-101 in Patients w/ Mayo Stage IIIb AL Amyloid
Protocol No
CAELUM-CAEL101-301
Sub Category
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscrasia Treatment-Naïve Patients with Mayo Stage IIIa AL Amyloidosis
A Study to Evaluate the Effectiveness & Safety of CAEL-101 in Patients w/ Mayo Stage IIIa AL Amyloid
Protocol No
CAELUM-CAEL101-302
Sub Category
An Open-Label, Phase 1/2 Study of JCAR017 in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (017004)
Study Evaluating Safety and Efficacy of JCAR017 in Subject with rrCLL or SLL
Protocol No
JUNO-017004-TRANSCEND-CLL
Sub Category
An open-label, Phase 2a/2b study of KRT-232 in subjects with Primary Myelofibrosis (PMF), Post Polycythemia Vera MF (Post PV-MF), or Post Essential Thrombocythemia MF (Post ET-MF) who have failed prior treatment with a JAK inhibitor
KRT-232 in Subjects With PMF, Post-PV MF, or Post-ET MF Who Have Failed a JAK Inhibitor
Protocol No
KARTOS-KRT-232-101-MF
Sub Category
GILEAD-5F9009-MDS: ENHANCE: A Randomized, Double-blind, Multicenter Study Comparing Magrolimab in Combination with Azacitidine versus Azacitidine Plus Placebo in Treatment-naïve Patients with Higher Risk MDS
Magrolimab + Azacitidine versus Azacitidine + Placebo in Untreated MDS
Protocol No
FORTYSEVEN-5F9009-MDS
Sub Category
A Phase I Trial of Neihulizumab Monotherapy for Standard-Risk Acute GVHD
A Phase I Trial of Neihulizumab Monotherapy for Standard-Risk Acute GVHD
Protocol No
IIT-ABEDIN-NEIHULIZUMAB
Sub Category
A Phase I Study of Neihulizumab (AbGn-168H) in Patients with Steroid-refractory Acute Graft-Versus-Host Disease (sr-aGvHD)
Neihulizumab (AbGn-168H) in patients with steroid-refractory acute graft-versus-host disease
Protocol No
ABGENOMICS-2017-002-01
Sub Category
Phase 1 Study of Redirected Autologous T Cells Engineered to Contain an Anti-CD19 and Anti-CD20 scFv Coupled to CD3-zeta; and 4-1BB Signaling Domains in Pediatric and Young Adult Patients with Relapsed and/or Refractory CD19 or CD20 B-cell Acute Lymphoblastic Leukemia
Phase 1 Study of CAR-20/19-T Cells in Pediatric and Young adult Patients with R/R B Cell ALL
Protocol No
IIT-TALANO-CART-ALL
Sub Category
A Phase 1/2 Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins: Phase 1 (done) and Phase 2 (Dose Expansion of CPI- 0610 with and without Ruxolitinib in Patients with MF)
A Phase 2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Myelofibrosis
Protocol No
CONSTELLATION-0610-02
Sub Category
A Phase Ib/II Study of Venetoclax (ABT-199) in Combination with Liposomal Vincristine in Patients with Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia
Venetoclax and Liposomal Vincristine in Patients with Relapsed or Refractory T-cell or B-cell ALL
Protocol No
ECOG-EA9152-ALL
Sub Category
A randomized 3-arm Phase II study comparing 1) Bendamustine, Rituximab and high dose Cytarabine (BR/CR), 2) Bendamustine, Rituximab, high dose Cytarabine and Acalabrutinib (BR/CR-A), and 3) Bendamustine, Rituximab and Acalabrutinib (BR-A) in patients </= 70 years old with untreated Mantle Cell Lymphoma
Comparison of BR/CR, BR/CR-A, and BR-A in patients under 70 with untreated MCL.
Protocol No
ECOG-EA4181-MCL
Sub Category
A Phase 3 Randomized Study Comparing JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA, versus Pomalidomide, Bortexomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Subjects with Relapsed and Lenalidomide-Refractory Multiple Myeloma
NJ-68284528 a CAR-T directied against BCMA vs PVd or DPd in pt with rr MM (CARTITUDE-4)
Protocol No
JANSSEN-JNJ-68284528-MMY3002
Sub Category
A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Single Agent Belantamab Mafodotin Compared to Pomalidomide plus Low-dose Dexamethasone (pom/dex) in Participants with Relapsed/Refractory Multiple Myeloma (RRMM)
Belantamab mafodotin vs pom/dex in RRMM
Protocol No
GSK-207495-DREAMM-03
Sub Category
A Randomized Phase II Study of Ruxolitinib (NSC-752295) in Combination with BCR-ABL Tyrosine Kinase Inhibitors in CML Patients with Molecular Evidence of Disease
Ruxolitinib Phosphate and Dasatinib or Nilotinib in Treating Patients With Chronic Myeloid Leukemia
Protocol No
SWOG-S1712-CML
Sub Category
Randomized Phase II/III Study Of Venetoclax (Abt 199) Plus Chemoimmunotherapy For Myc/Bcl2 Double-Hit And Double Expressing Lymphomas
Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas
Protocol No
ALLIANCE-A051701-DLBCL
Sub Category
Composite Health Assessment Risk Model for Older Adults: Applying Pre-transplant Comorbidity, Geriatric Assessment and Biomarkers to Predict Non-Relapse Mortality after Allogeneic Transplantation in Older Adults
Composite Health Assessment Risk Model (CHARM) for Older Adults
Protocol No
CTN-1704
Sub Category
A Phase II Study of the Efficacy and Pharmacogenomics of Salvage Cladribine, Cytarabine, Mitoxantrone, G-CSF (CLAG-M) Chemotherapy in Patients with Relapse/Refractory and Secondary Acute Myeloid Leukemia (AML)
Efficacy and Pharmacogenomics of Salvage CLAG-M Chemotherapy in Patients With Relapse/Refractory and Secondary Acute Myeloid Leukemia
Protocol No
IIT-ATALLAH-CLAGM-AML
Sub Category
A Phase II, Open-Label, Study of Propylene Glycol-Free Melphalan HCL (EVOMELA®) in Combination with Fludarabine and Total Body Irradiation Based Reduced Intensity Conditioning for Haploidentical Transplantation
EVOMELA In Combination With Fludarabine and TBI based reduced intensity conditioning for Haplo BMT
Protocol No
IIT-HAMADANI-FLU-MEL-TBI
Sub Category